A DaTscan is a specialized brain imaging test that measures the health of dopamine-producing nerve cells by detecting how much dopamine transporter protein remains in a region of the brain called the striatum. It uses a radioactive tracer called ioflupane (labeled with iodine-123) that binds specifically to dopamine transporters, and the resulting image is captured with a type of nuclear medicine camera called SPECT. Doctors order it most often when they cannot tell from a clinical exam alone whether a patient’s tremor, stiffness, or slowness of movement stems from a neurodegenerative condition like Parkinson’s disease or from something else entirely, such as essential tremor or medication side effects.
How the Scan Works
Dopamine transporters are proteins that sit on the surface of nerve endings in the striatum, a pair of deep brain structures involved in movement control. In healthy brains, these transporters are abundant. In Parkinson’s disease and related neurodegenerative conditions, the nerve cells that produce dopamine gradually die off, and the number of transporters drops with them. Ioflupane is a synthetic molecule designed to latch onto whatever dopamine transporters remain. Once it’s injected into a vein, it crosses into the brain and concentrates in the striatum over a few hours. The iodine-123 attached to the molecule emits gamma rays, which the SPECT camera detects from outside the skull, producing a cross-sectional image of tracer distribution.
The result is essentially a map of dopamine transporter density. Where transporters are plentiful, the image lights up. Where they’ve been lost, the signal fades. Standard clinical SPECT cameras produce images at a resolution that is adequate for seeing gross patterns of loss in the striatum. Newer research-grade pinhole SPECT systems have pushed resolution down to around 2.5 millimeters in phantom scans, potentially allowing finer detail in the future, though conventional hospital scanners remain the clinical standard.1Physics in Medicine & Biology. Optimized image acquisition for dopamine transporter imaging with ultra-high resolution clinical pinhole SPECT
When Doctors Order a DaTscan
The primary reason for ordering a DaTscan is diagnostic uncertainty. A neurologist who is confident a patient has Parkinson’s disease based on the clinical picture usually does not need the scan. It becomes useful when the presentation is ambiguous, particularly in early disease when symptoms overlap with other conditions. The scan has been proven helpful in the differential diagnosis between Parkinson’s disease and essential tremor, and in confirming dopaminergic degeneration in patients with parkinsonism whose cause is unclear.2PubMed. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease? It is also a recognized tool for distinguishing Parkinson’s disease from non-degenerative tremors, while other imaging modalities like cardiac MIBG SPECT and FDG-PET serve different roles in separating Parkinson’s from atypical parkinsonism syndromes such as multiple system atrophy or progressive supranuclear palsy.3Clinical Medicine. Imaging in Parkinson’s disease
A second important use involves dementia. When a patient develops cognitive decline along with movement symptoms or visual hallucinations, the question often arises whether they have dementia with Lewy bodies or Alzheimer’s disease. These two conditions call for very different management approaches, and the clinical overlap can be significant. A DaTscan helps because dopamine transporter loss is a hallmark of Lewy body dementia but is not typically present in Alzheimer’s.4PubMed Central. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a us perspective of current guidelines and future directions Ioflupane imaging has been shown to significantly improve the ability to distinguish between these two conditions during a patient’s lifetime, which is something clinical assessment alone struggles with.5PubMed. Dementia with Lewy bodies versus Alzheimer’s disease: role of dopamine transporter imaging
What the Images Show
A normal DaTscan image has a distinctive appearance that radiologists sometimes describe as a “comma” or “crescent” shape on each side of the brain, reflecting healthy tracer uptake throughout the caudate nucleus and putamen. When dopamine neurons have degenerated, the image changes. The posterior putamen tends to lose signal first, often on one side before the other, creating a lopsided or shrunken pattern. In advanced cases, both the putamen and caudate show reduced uptake, leaving only faint dots where the crescents should be.
The pattern of loss matters as much as the degree. In a study of over a hundred patients with non-Parkinson’s movement disorders, about three-quarters showed some abnormality on visual assessment, but nearly all of those abnormalities were mild to moderate decreases in tracer uptake rather than the severe, asymmetric loss typical of Parkinson’s disease. The most commonly affected region was the left posterior putamen, followed by the right posterior putamen, then the anterior putamen, and finally the caudate on each side. When the same images were subjected to quantitative scoring, only about 14% of those patients had abnormalities severe enough to generate a truly abnormal statistical score.6Reports in Medical Imaging. Identification of patterns of abnormalities seen on DaTscan™ SPECT imaging in patients with non-Parkinson’s movement disorders This gap between what looks mildly off to the eye and what crosses a statistical threshold is one reason interpretation requires experience.
In clinical practice, images are read both visually and with the help of semi-quantitative software that calculates uptake ratios for the caudate and putamen and compares them to age-matched normal databases. Visual assessment by trained readers performs well: in one study of early Parkinson’s patients, visual reads achieved a sensitivity of 94% and a specificity of 92%, with a false-positive rate of only about 1.4% and a false-negative rate of roughly 5%. These figures were comparable to those produced by the quantitative software.7PubMed Central. Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism Separate work using receiver operating characteristic analysis identified a striatal binding ratio cutoff of 3.8, yielding a sensitivity above 98% and a specificity of 95% for detecting parkinsonian syndromes.8PubMed. Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies
How Accurate Is a DaTscan?
Accuracy depends on the clinical context. The scan performs best when the question is whether a patient’s symptoms are caused by loss of dopamine neurons or by something that leaves those neurons intact. A systematic review examining diagnostic accuracy in patients with established Parkinson’s disease found sensitivity rates of 100% across multiple studies, with specificity also reaching 100% in the one study that included enough non-Parkinson’s controls to calculate it.9PubMed Central. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review In patients with clinically uncertain parkinsonism from that same review, sensitivity and specificity both reached about 98%.
Early-stage disease is trickier. When DaTscan images were compared to the clinical diagnosis that experts settled on three years later, the scan’s sensitivity at baseline was 78% and its specificity was about 97%.10Journal of Nuclear Medicine. Accuracy of DaTscan™ (Ioflupane I 123 Injection) in diagnosis of early parkinsonian syndromes (PS) In other words, the scan is very good at correctly ruling out Parkinson’s when it is truly absent, but it may miss a modest fraction of very early cases before enough dopamine transporters have been lost to show up on the image. Sensitivity does climb as the disease progresses. Reported sensitivity figures across clinical evaluations range from 79% to 100%, with specificity consistently in the high 90s, around 97% to 98%. A negative scan therefore makes Parkinson’s less likely but does not completely rule it out, particularly in the earliest stages.
How DaTscan Results Change Diagnoses and Treatment
The scan’s value is ultimately measured by whether it changes what doctors do. The evidence on this point is striking. A systematic review and meta-analysis pooling data from multiple studies found that roughly 31% of patients had their diagnosis changed after the scan, and about 54% had a change in their clinical management, whether that meant starting, stopping, or switching medications.11npj Parkinson’s Disease. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis In most studies, management changes exceeded diagnostic changes, meaning the scan often prompted medication adjustments even when it confirmed rather than overturned the working diagnosis.
A separate retrospective study found that physicians reported the DaTscan influenced their diagnosis in 68% of patients and affected clinical management in 58%.12PubMed Central. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study Another study from a clinically uncertain parkinsonism cohort found that the scan changed the clinical diagnosis in about 40% of patients and led to medication changes in 70%.13PubMed Central. Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease Those numbers make DaTscan one of the more impactful diagnostic tests in neurology, particularly for a disease where the traditional gold standard is the clinical impression of a movement disorder specialist.
The conditions most prone to diagnostic revision after a DaTscan tend to be the ones that most closely mimic Parkinson’s. A meta-analysis focused on clinically uncertain cases found an overall diagnostic revision rate of about 32%. When broken out by initial diagnosis, revisions were most common in patients originally suspected of having vascular parkinsonism (about 53% revised), followed by drug-induced parkinsonism (38%), functional movement disorder (35%), essential tremor (27%), and even patients already labeled as having Parkinson’s disease (about 22%).14Journal of Clinical Neuroscience. Clinical utility of DaTscan in clinically uncertain parkinsonian syndromes: a systematic review and meta‑analysis The fact that one in five patients thought to have Parkinson’s had their diagnosis revised after scanning underscores how uncertain clinical assessment alone can be.
What a DaTscan Cannot Tell You
The scan has a fundamental blind spot: it shows dopamine transporter loss but cannot tell you why the loss occurred. Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration all destroy dopamine neurons through different pathological processes, but they produce similar-looking DaTscan abnormalities. So a scan that comes back abnormal confirms that something neurodegenerative is happening, but additional clinical context, other imaging, and sometimes time are needed to determine which specific disease is responsible.
The scan excels at a binary question: is there dopamine neuron loss or not? It separates neurodegenerative parkinsonism from conditions that mimic it without destroying those neurons, such as essential tremor, drug-induced parkinsonism, and psychogenic (functional) movement disorders. But it does not reliably distinguish one neurodegenerative cause from another. That limitation matters because treatments for Parkinson’s disease differ from those for progressive supranuclear palsy or corticobasal degeneration, and patients with multiple system atrophy have a different prognosis. Other imaging tools, including FDG-PET and cardiac MIBG scintigraphy, can help with those secondary distinctions.
There is also the question of false negatives in very early disease. A person with only minimal dopamine neuron loss may produce a scan that looks normal or borderline. In such cases, a follow-up scan a year or two later may reveal the expected pattern. Only about 2% of patients in one systematic review had their DaTscan results change between an initial scan and a follow-up.9PubMed Central. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review That is a small number but not zero, and it reinforces the point that a single normal scan in a patient whose symptoms are progressing may warrant reassessment.
What to Expect During the Procedure
The test itself is straightforward but takes most of a day. You receive an intravenous injection of the ioflupane tracer and then wait three to six hours for it to accumulate in the brain. During the wait you can eat, drink, and move around normally. When it’s time for the scan, you lie flat on a table with your head positioned in a head holder, and the SPECT camera rotates slowly around your head for roughly 30 to 45 minutes. Staying still is important for image quality but there is no pain involved beyond the initial injection.
Before the injection, you’ll typically be given a medication to block your thyroid from absorbing any free iodine released by the tracer. This is usually potassium iodide, Lugol’s solution, or potassium perchlorate, taken by mouth an hour or so before the injection. The purpose is to reduce unnecessary radiation exposure to the thyroid gland. Current practice calls for standardized thyroid protection, though there is ongoing discussion about whether a more flexible, patient-by-patient approach might be appropriate in some clinical settings.15Nuclear Medicine Communications. Thyroid protection for 123 I meta-iodobenzylguanidine and 123 I ioflupane (DaTScan) diagnostic imaging: historical context, current evidence, and clinical perspectives
Certain medications can interfere with the scan by competing for the same binding sites on dopamine transporters. Your doctor will typically ask you to pause drugs like bupropion, certain ADHD stimulants, cocaine (if relevant), and some antidepressants before the test. The specific washout period varies by drug. Levodopa and most dopamine agonists used to treat Parkinson’s disease do not significantly affect the scan and usually do not need to be stopped.
Cost-Effectiveness
A DaTscan is not cheap. In the United States, the tracer alone costs over a thousand dollars, and the total bill for the procedure including facility and reading fees can run considerably higher. Insurance coverage varies, though Medicare and many private insurers do cover it when the clinical indication is appropriate. The question of whether the expense is worth it has been formally studied.
An economic modeling analysis from Italy compared the DaTscan pathway with clinical judgment alone for patients referred to movement disorder specialists to differentiate essential tremor from Parkinson’s disease. Over five years, patients in the DaTscan arm spent more time on the correct therapy and actually cost the healthcare system less per patient, saving about 440 euros on average. The scan was cost-saving when the prevalence of Parkinson’s among patients being tested was under 55%, and remained cost-effective up to a prevalence of 70%.16PubMed. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson’s disease in Italy The savings come from getting patients onto the right treatment faster, avoiding years of medications that don’t help, and reducing unnecessary follow-up visits driven by diagnostic uncertainty. Healthcare systems differ, but the general principle holds: the scan’s upfront cost is often offset by downstream savings when it resolves a genuinely uncertain diagnosis.
Lewy Body Dementia and the Expanding Role of DaTscan
The use of DaTscan in suspected Lewy body dementia deserves extra attention because it addresses a clinical problem that is both common and consequential. Lewy body dementia is the second most common neurodegenerative dementia after Alzheimer’s, and misdiagnosis rates are high. Patients with Lewy body dementia can have severe, sometimes dangerous reactions to certain antipsychotic medications that might be prescribed if Alzheimer’s is assumed. They also respond better to cholinesterase inhibitors than typical Alzheimer’s patients do, making correct identification clinically meaningful.
Because Lewy body dementia involves degeneration of dopamine neurons while Alzheimer’s generally does not, the DaTscan offers a clear biological signal to separate the two. In clinical scenarios where a patient has fluctuating cognition, visual hallucinations, and subtle motor signs, the scan can break the tie.4PubMed Central. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a us perspective of current guidelines and future directions Current diagnostic criteria for Lewy body dementia include an abnormal DaTscan as one of the “indicative biomarkers,” meaning a positive scan can elevate a diagnosis from “possible” to “probable.” This is one of the few situations in dementia care where a single imaging test can meaningfully shift the diagnostic category and, by extension, the treatment approach.
Medications That Affect the Scan
One of the practical headaches around DaTscan is the list of drugs that can artificially lower the signal by occupying the dopamine transporter binding site before the tracer arrives. The result is a falsely abnormal scan in someone whose dopamine neurons are actually intact. The drugs most likely to cause this problem include certain antidepressants (particularly those that block dopamine or norepinephrine reuptake), stimulant medications, and recreational drugs like cocaine and amphetamines. Selective serotonin reuptake inhibitors (SSRIs) were once thought to be a major concern, but more recent evidence suggests their effect on DaTscan results is minimal, and most centers no longer require patients to stop them.
Conversely, the medications most commonly prescribed for Parkinson’s disease itself, levodopa and dopamine agonists like pramipexole and ropinirole, do not interfere with the scan. They work on different parts of the dopamine system (postsynaptic receptors or dopamine synthesis) rather than on the transporter protein the tracer targets. This means a patient already being treated for suspected Parkinson’s can generally undergo the scan without interrupting their symptom management, which is a practical advantage over some other diagnostic tests that require drug washouts.
If you’re scheduled for a DaTscan, your neurologist or nuclear medicine physician should review your full medication list and advise on what to stop and how far in advance. The washout period varies from a few days for some drugs to several weeks for others, depending on how tightly they bind to the transporter and how long they stay in your system. Getting this right matters: a scan performed on interfering medications wastes time and money and can lead to a wrong diagnosis.